<DOC>
	<DOCNO>NCT01480583</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability GRN1005 patient brain metastasis breast cancer . For patient HER2 positive metastatic breast cancer , GRN1005 assess combination Trastuzumab ( Herceptin® ) per standard-of-care practice . In addition , study evaluate ability 18F-FLT determine amount change uptake brain metastasis breast cancer GRN1005 treatment , correlate intra-cranial response ( patient enrol NCI ) .</brief_summary>
	<brief_title>GRN1005 Alone Combination With Trastuzumab Breast Cancer Patients With Brain Metastases</brief_title>
	<detailed_description>Please see Brief Summary section .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Alovudine</mesh_term>
	<criteria>Key 1 . Age ≥ 18 year 2 . Histologically cytologicallydocumented breast cancer ( HER2 status ER/PgR status must know ) 3 . Brain metastasis breast cancer without prior WBRT 4 . At least one radiologicallyconfirmed measurable metastatic brain lesion ( ≥ 1.0 cm long diameter ) GdMRI brain &lt; 14 day prior first dose ( Metastatic brain lesion previously treat SRS may target nontarget lesion ) 5 . Patients must neurologically stable : On stable dos corticosteroid anticonvulsant ( EIAEDs , include phenytoin , phenobarbitol , carbamazepine , fosphenytoin , primidone , oxcarbazepine ) ≥ 5 day prior obtain baseline GdMRI brain ≥ 5 day prior first dose 6 . KPS ≥ 70 % 7 . Completed WBRT intracranial lesion ≥ 28 day prior first dose Key 1 . NCI CTCAE v4.0 Grade ≥ 2 neuropathy 2 . CNS disease require immediate neurosurgical intervention ( e.g. , resection , shunt placement , etc . ) 3 . Known leptomeningeal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>GRN1005</keyword>
	<keyword>ANG1005</keyword>
	<keyword>Peptide-Drug Conjugate ( PDC )</keyword>
	<keyword>LRP-1</keyword>
	<keyword>Targeted Therapy</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Brain Metastases</keyword>
	<keyword>Brain Tumor</keyword>
	<keyword>Blood Brain Barrier</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Taxol</keyword>
	<keyword>Breast cancer brain metastasis</keyword>
</DOC>